STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that (KL) or (KP) comutations define distinct subgroups of -mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly amo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer discovery 2018-07, Vol.8 (7), p.822-835
Hauptverfasser:	Skoulidis, Ferdinandos, Goldberg, Michael E, Greenawalt, Danielle M, Hellmann, Matthew D, Awad, Mark M, Gainor, Justin F, Schrock, Alexa B, Hartmaier, Ryan J, Trabucco, Sally E, Gay, Laurie, Ali, Siraj M, Elvin, Julia A, Singal, Gaurav, Ross, Jeffrey S, Fabrizio, David, Szabo, Peter M, Chang, Han, Sasson, Ariella, Srinivasan, Sujaya, Kirov, Stefan, Szustakowski, Joseph, Vitazka, Patrik, Edwards, Robin, Bufill, Jose A, Sharma, Neelesh, Ou, Sai-Hong I, Peled, Nir, Spigel, David R, Rizvi, Hira, Aguilar, Elizabeth Jimenez, Carter, Brett W, Erasmus, Jeremy, Halpenny, Darragh F, Plodkowski, Andrew J, Long, Niamh M, Nishino, Mizuki, Denning, Warren L, Galan-Cobo, Ana, Hamdi, Haifa, Hirz, Taghreed, Tong, Pan, Wang, Jing, Rodriguez-Canales, Jaime, Villalobos, Pamela A, Parra, Edwin R, Kalhor, Neda, Sholl, Lynette M, Sauter, Jennifer L, Jungbluth, Achim A, Mino-Kenudson, Mari, Azimi, Roxana, Elamin, Yasir Y, Zhang, Jianjun, Leonardi, Giulia C, Jiang, Fei, Wong, Kwok-Kin, Lee, J Jack, Papadimitrakopoulou, Vassiliki A, Wistuba, Ignacio I, Miller, Vincent A, Frampton, Garrett M, Wolchok, Jedd D, Shaw, Alice T, Jänne, Pasi A, Stephens, Philip J, Rudin, Charles M, Geese, William J, Albacker, Lee A, Heymach, John V
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenocarcinoma of Lung - drug therapy Adenocarcinoma of Lung - genetics Adenocarcinoma of Lung - metabolism Adenocarcinoma of Lung - therapy Adult Aged Aged, 80 and over Animals Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Disease Models, Animal Drug Resistance, Neoplasm - genetics Humans Immunotherapy Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Lung Neoplasms - therapy Male Mice Middle Aged Mutation Nivolumab - pharmacology Nivolumab - therapeutic use Prognosis Programmed Cell Death 1 Receptor - antagonists & inhibitors Progression-Free Survival Protein-Serine-Threonine Kinases - genetics Proto-Oncogene Proteins p21(ras) - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!